Publicações

Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer: Phase Iii Keynote-)181 Study.

AuthID
P-00R-4YX

Author(s)

Kojima, T

Muro, K

Francois, E

Hsu, CH

Moriwaki, T

Kim, SB

Lee, SH

Bennouna, J

Kato, K

Lin, S

Qin, SQ

Ferreira, P

Doi, T

Adenis, A

Enzinger, PC

Shah, MA

Wang, RX

Bhagia, P

Kang, SP

Metges, JP

Document Type

Abstract

Year published

2019

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 37, Issue: 4

Conference

Gastrointestinal Cancers Symposium, Date: JAN 17-19, 2019, Location: San Francisco, CA

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1200/jco.2019.37.4_suppl.2

Wos: WOS:000489107600050

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer: Phase Iii Keynote-)181 Study.

Useful Links

Get Help

Autenticação Federada (Click on the image)

Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer: Phase Iii Keynote-)181 Study.

Useful Links

Get Help